Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 35, 305-309, February 1, 1975]
© 1975 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coombs, M. M.
Right arrow Articles by Vose, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coombs, M. M.
Right arrow Articles by Vose, C. W.

The Relationship between Metabolism, DNA Binding, and Carcinogenicity of 15,16-Dihydro-11-methylcyclopenta[a]phenanthren-17-one in the Presence of a Microsomal Enzyme Inhibitor

Maurice M. Coombs, Tarlochan S. Bhatt and Colin W. Vose1

Chemistry Department, Imperial Cancer Research Fund Laboratories, Lincoln's Inn Fields, London WC2A 3PX, England

The mean latent period for skin tumor production by the carcinogen 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17-one (Compound IVb) in the mouse was 30 weeks for a dose of 60 µg/week and about 45 weeks for 60 µg/week, while at 0.6 µg/week, no tumors were observed during 100 weeks. Simultaneous administration of the closely related noncarcinogen (IVa) (54 µg/week) together with the carcinogen at 60 µg/week had no effect on the mean latent period. Simultaneous administration of a threefold quantity of the microsomal enzyme inhibitor 7,8-benzoflavone (I) with the carcinogen at the highest dose increased the mean latent period to 38 weeks, while at the intermediate dose it completely suppressed tumor formation.

Neither ketone IVa nor IVb bound covalently to calf thymus DNA in vitro without prior metabolic activation. After incubation with rat liver microsomes and NADPH in the presence of air, both ketones bound covalently to added DNA in vitro, the noncarcinogen (IVa) about four times more extensively than the carcinogen (IVb), roughly in proportion to the overall extents to which these ketones were metabolized. In contrast, overall metabolism of the carcinogen (IVb) was somewhat increased by the addition of a threefold quantity of the inhibitor (I) to the incubation mixture, but binding to added DNA was almost completely prevented.

These results are discussed in connection with the hypothesis that cellular DNA is the target of the carcinogen (IVb) for tumor initiation.

1 Recipient of a research bursary from the Imperial Cancer Research Fund. Present address: Metabolic Studies Laboratory, G. D. Searle & Co. Ltd., Lane End Road, High Wycombe, Bucks HP12 4HL, England.

Received 6/17/74. Accepted 10/14/74.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1975 by the American Association for Cancer Research.